Dabitou& reg;， As a celebrity "Jinbo Baby", we have participated in the exhibition for seven consecutive years and have launched new products every year, creating this extraordinary record.
This year, global biopharmaceutical giant Sanofi once again brings its "flagship product" Dabitou& reg; Appearing at this year's CIIE, Dabitou& reg; It showcased its newly approved indications for chronic obstructive pulmonary disease and a new pre filled injection pen - this is the first exhibition in China.
It is reported that Dabitou& reg; In September of this year, it was the first to receive approval in China, ahead of the US FDA, becoming the first and only targeted therapy drug for chronic obstructive pulmonary disease, ending the decade long stagnation of innovative therapies in this field and opening a new chapter in targeted therapy. In addition, its approval speed has set a "miracle" in China, taking less time than the European Union and the United States, once again breaking the record for innovative drugs benefiting Chinese patients.
The first exhibition of the new pre filled injection pen provides patients with more convenient treatment options. Type 2 inflammatory diseases, such as atopic dermatitis and asthma, are chronic diseases that require long-term treatment. The portability and ease of operation of the new pre filled injection pen significantly improve the convenience of medication for patients and assist them in long-term self-management. It is reported that Sanofi plans to prioritize the supply of this new pre filled injection pen in the Chinese market.
Dabitou& reg; Exhibiting for seven consecutive years without interruption, it has brought seven pioneering indications. Driven by the strong "spillover effect" at the CIIE, Dabitou& reg; Created multiple industry firsts for imported drugs in China, including first exhibition, approval, market launch, first dose, and entry into medical insurance, creating multiple "first and only" Chinese records.
Based on a deep understanding of the type 2 inflammatory pathway, interleukin 4 and 13 antagonists have brought innovative therapies for various type 2 inflammatory diseases. Its indications cover multiple treatment areas such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease. In order to better understand the treatment and survival status of patients with type 2 inflammatory diseases, respiratory and dermatological experts jointly initiated the "Research on the Treatment Status and Quality of Life of Chinese Type 2 Inflammatory Comorbidity Patients" during this year's CIIE, aiming to explore the unmet diagnosis and treatment needs of patients and explore more innovative diagnosis and treatment solutions for patients.
Dabitou& reg; Undoubtedly, he is an outstanding representative of the powerful "spillover effect" at the CIIE. Xie Lijuan, General Manager of Sanofi Pharmaceuticals China, said that thanks to the "spillover effect" at the CIIE, Dabitou& reg; It has become a symbol of "Chinese speed" and is currently listed in seven indications in China, covering the fields of dermatology and respiration. In China, immune inflammatory diseases caused by type 2 inflammation, such as atopic dermatitis and type 2 asthma, are becoming increasingly common. The CIIE not only raised the attention of various sectors of society to the unmet needs of these diseases, showcased cutting-edge innovative therapies, but also promoted multi-party cooperation through an open and innovative platform, enhanced diagnosis and treatment capabilities, and optimized patient experience.
In China, the incidence of immune inflammatory diseases mediated by type 2 inflammation is constantly increasing. From pioneering a new era in the treatment of atopic dermatitis to revolutionizing medical practice in the respiratory field, Dabitou& reg; Every step forward in the field of type 2 inflammation has brought hope to Chinese patients with innovative frontiers.
Sanofi has always focused on the field of immunology, with immunological science at the core of its global research and development strategy. China is one of Sanofi's key markets, and Dabitou& reg; As an important milestone for Sanofi in the field of immunology, it continues to drive innovation in this area. Currently, Dabitou® Seven major indications have been approved in China, including skin diseases such as atopic dermatitis and nodular prurigo, as well as respiratory diseases such as asthma and chronic obstructive pulmonary disease. By gaining a deeper understanding of the type 2 inflammatory pathway, Sanofi will continue to accelerate the expansion of Dapidor& reg; The potential for application in other type 2 inflammatory diseases Xie Lijuan said.
Meanwhile, Sanofi's reserve forces are already on their way. According to Xie Lijuan, looking ahead, Sanofi has established a product pipeline consisting of 12 heavyweight drugs and vaccines, of which 3 have already launched registration and research and development strategies in China. Sanofi is accelerating the introduction of more innovative products and solutions for Chinese patients, and we look forward to more Chinese patients being able to use cutting-edge innovative therapies in sync with the world.
With the help of CIIE, many multinational pharmaceutical companies have chosen to introduce globally leading innovative drugs and therapies into China, and multiple innovative products have also transformed from exhibits to commodities, continuously driving multinational pharmaceutical companies to accelerate their layout in the Chinese market. Sanofi has witnessed and participated in the rapid development of the Chinese pharmaceutical market for over 40 years. In recent years, Sanofi has been promoting the introduction of innovative products at an unprecedented "Chinese speed", such as the "Jinbo Baby" Dabitou; reg; The journey of going public in China is an excellent example.
We have set a goal of introducing 25 innovative products and indications in China from 2020 to 2025, which has been achieved ahead of schedule by 2023. Sanofi regards China as an important market for global synchronous research and development, and has participated in over 90% of global synchronous research and development projects. Through cooperation with local partners, we explore innovative solutions to better meet the diverse needs of Chinese patients, "said Xie Lijuan.